Celator Pharmaceuticals celatorpharma.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Celator Pharmaceuticals is a pharmaceutical company developing new and effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents an approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products; CPX-351 (a liposomal form...Show all

Celator Pharmaceuticals is a pharmaceutical company developing new and effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents an approach that identifies molar ratios of drugs that will deliver a syne...Show all

Company (Acquired)

Phone: 609-243-0123

Fax:

303B College Road East

Princeton, 08540
New Jersey, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Celator Pharmaceuticals $200M Jul 13, 2016
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Celator Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors

Competitors

Company Status Description Investors

Cequent Pharmaceuticals

Cambridge, Massachusetts, United States
AcquiredCequent is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.Login to see details

Novacea

South San Francisco, California, United States
IPO / Went publicNovacea is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including AsentarTM, which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions for delivery of drug combinations Apr 16, 2004 Mar 01, 2016 Patent
Lipid carrier compositions with enhanced blood stability Nov 13, 2002 Aug 27, 2013 Patent
Taxane delivery system Nov 26, 2008 Jul 16, 2013 Patent
Liposomal formulations of anthracycline agents and cytidine analogs Sep 20, 2011 Apr 30, 2013 Patent
Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Feb 15, 2008 Jan 10, 2012 Patent
See all 14 patents